<DOC>
	<DOCNO>NCT02099110</DOCNO>
	<brief_summary>This study co-administration ertugliflozin ( MK-8835/PF-04971729 ) sitagliptin give together alone along metformin participant type 2 diabetes mellitus ( T2DM ) inadequate glycemic control metformin monotherapy . The primary hypothesis study ertugliflozin 15 mg daily plus sitagliptin 100 mg daily provide great hemoglobin A1C ( A1C ) -lowering compare sitagliptin 100 mg daily alone .</brief_summary>
	<brief_title>Ertugliflozin Sitagliptin Co-administration Factorial Study ( MK-8835-005 )</brief_title>
	<detailed_description>This study include 1-week screening period ; 12-week metformin titration/dose stabilization period ; 2-week single-blind placebo run-in period ; 52-week ( 26-week Phase A ( 26-week Phase B ) double-blind treatment period post-treatment telephone contact 14 day last dose study medication .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes mellitus per American Diabetes Association guideline On metformin monotherapy ( &gt; =1500 mg/day ) &gt; =8 week Visit 1/Screening A1C &gt; =7.5 % &lt; =11.0 % ( &gt; =58 mmol/mol &lt; =97 mmol/mol ) OR On metformin monotherapy ( &gt; =1500 mg/day ) &lt; 8 week Visit 1/Screening A1C &gt; =7.5 % &lt; =11.0 % ( &gt; =58 mmol/mol &lt; =97 mmol/mol ) OR On metformin monotherapy &lt; 1500 mg/day Visit 1/Screening A1C &gt; =8.0 % &lt; =11.5 % ( &gt; =64 mmol/mol &lt; =102 mmol/mol ) Body mass index ( BMI ) &gt; =18.0 kg/m^2 Male female reproductive potential Female reproductive potential agrees remain abstinent heterosexual activity use 2 acceptable combination contraception History type 1 diabetes mellitus ketoacidosis History specific type diabetes ( e.g. , genetic syndrome , secondary pancreatic diabetes , diabetes due endocrinopathies , drug chemicalinduced , postorgan transplant A know hypersensitivity intolerance sodium glucose cotransporter ( SGLT2 ) inhibitor sitagliptin Has treat follow agent within 12 week study start prerandomization period : Insulin type ( except shortterm use [ i.e. , &lt; =7 day ] concomitant illness stress ) , injectable antihyperglycemic agent ( e.g. , pramlintide , exenatide , liraglutide ) , pioglitazone rosiglitazone , sodium glucose cotransporter 2 ( SGLT2 ) inhibitor , alpha glucosidase inhibitor meglitinides , dipeptidylpeptidase 4 inhibitor ( DPP4 inhibitor ) , sulfonylurea ( SUs ) , bromocriptine ( Cycloset™ ) , colesevelam ( Welchol™ ) , AHA exception protocolapproved agent Is weightloss program weightloss medication medication associate weight change weight stable prior study start Has undergone bariatric surgery within past 12 month &gt; 12 month weight stable prior study start A history myocardial infarction , unstable angina , arterial revascularization , stroke , transient ischemic attack , New York Heart Association ( NYHA ) functional class IIIIV heart failure within 3 month study start Active , obstructive uropathy indwell urinary catheter History malignancy &lt; =5 year prior study start , except adequately treat basal cell squamous cell skin cancer situ cervical cancer A know history human immunodeficiency virus ( HIV ) A blood dyscrasia disorder cause hemolysis unstable red blood cell , clinically important hematological disorder ( e.g . aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) A medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Any clinically significant malabsorption condition Current treatment hyperthyroidism On thyroid replacement therapy stable dose least 6 week prior study start On previous clinical study ertugliflozin eGFR ( use 4variable Modification Diet Renal Disease Study Equation ( MDRD ) equation ) &lt; 60 mL/min/1.73 m^2 Serum creatinine &gt; = 1.3 mg/dL ( 115 µmol/L ) males &gt; = 1.2 mg/dL ( 106 µmol/L ) females Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal Hemoglobin &lt; 12 g/dL ( 120 g/L ) males &lt; 11 g/dL ( 110 g/L ) female . Participated study involve investigational drug ( ) 30 day prior study start Surgical procedure within 6 week prior study start major surgery plan trial Positive urine pregnancy test Pregnant breastfeeding , plan conceive trial , include 14 day follow last dose study medication Planning undergo hormonal therapy preparation egg donation trial , include 14 day follow last dose study medication Routinely consume &gt; 2 alcoholic drink per day &gt; 14 alcoholic drink per week engages binge drink Donated blood blood product within 6 week study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>